{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:51:26Z","timestamp":1790664686672,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81503118"],"award-info":[{"award-number":["81503118"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"CAMS","doi-asserted-by":"publisher","award":["CAMS-I2M-1-010"],"award-info":[{"award-number":["CAMS-I2M-1-010"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81621064"],"award-info":[{"award-number":["81621064"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science and Technology","award":["2018ZX09711003"],"award-info":[{"award-number":["2018ZX09711003"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.antiviral.2019.03.005","type":"journal-article","created":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T10:21:21Z","timestamp":1552126881000},"page":"23-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["APOBEC3G is a restriction factor of EV71 and mediator of IMB-Z antiviral activity"],"prefix":"10.1016","volume":"165","author":[{"given":"Huiqiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuorong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.03.005_bib1","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1017\/S1462399409001343","article-title":"Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics","volume":"12","author":"Albin","year":"2010","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.antiviral.2019.03.005_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2017.03.009","article-title":"Direct-acting antivirals and host-targeting strategies to combat enterovirus infections","volume":"24","author":"Bauer","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2019.03.005_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000231","article-title":"APOBEC3G inhibits elongation of HIV-1 reverse transcripts","volume":"4","author":"Bishop","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.005_bib5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3201\/eid0904.020395","article-title":"Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes","volume":"9","author":"Cardosa","year":"2003","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.03.005_bib6","doi-asserted-by":"crossref","first-page":"16546","DOI":"10.1074\/jbc.M109.085308","article-title":"Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G","volume":"285","author":"Cen","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.03.005_bib7","doi-asserted-by":"crossref","first-page":"27761","DOI":"10.1074\/jbc.R109.052449","article-title":"Biochemical basis of immunological and retroviral responses to DNA-targeted cytosine deamination by activation-induced cytidine deaminase and APOBEC3G","volume":"284","author":"Chelico","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.03.005_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188640","article-title":"Epidemiological and genetic characteristics of EV71 in hand, foot, and mouth disease in Guangxi, southern China, from 2010 to 2015","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.03.005_bib9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/1471-2334-14-417","article-title":"The correlation between the presence of viremia and clinical severity in patients with enterovirus 71 infection: a multi-center cohort study","volume":"14","author":"Cheng","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.03.005_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1146\/annurev.immunol.26.021607.090350","article-title":"The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements","volume":"26","author":"Chiu","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2019.03.005_bib11","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/j.cub.2003.10.034","article-title":"The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G","volume":"13","author":"Conticello","year":"2003","journal-title":"Curr. Biol."},{"key":"10.1016\/j.antiviral.2019.03.005_bib13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1099\/vir.0.038919-0","article-title":"The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses","volume":"93","author":"Fehrholz","year":"2012","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2019.03.005_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1742-4690-5-51","article-title":"HIV-1 Vif, APOBEC, and intrinsic immunity","volume":"5","author":"Goila-Gaur","year":"2008","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2019.03.005_bib15","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1017\/S0950268817000309","article-title":"Epidemics and aetiology of hand, foot and mouth disease in Xiamen, China, from 2008 to 2015","volume":"145","author":"He","year":"2017","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.antiviral.2019.03.005_bib16","article-title":"N6-methyladenosine modification and METTL3 modulate enterovirus 71 replication","author":"Hao","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2019.03.005_bib17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.virusres.2008.07.015","article-title":"The circulation of subgenogroups B5 and C5 of enterovirus 71 in Taiwan from 2006 to 2007","volume":"137","author":"Huang","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2019.03.005_bib18","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1128\/JVI.02680-05","article-title":"Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect","volume":"80","author":"Iwatani","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.005_bib19","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1128\/JVI.03385-12","article-title":"Prototype foamy virus bet impairs the dimerization and cytosolic solubility of human APOBEC3G","volume":"87","author":"Jaguva Vasudevan","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.005_bib20","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.3390\/molecules18033630","article-title":"Synthesis and antiviral activity of N-phenylbenzamide derivatives, a novel class of enterovirus 71 inhibitors","volume":"18","author":"Ji","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.antiviral.2019.03.005_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003361","article-title":"Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA","volume":"9","author":"Kitamura","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.005_bib22","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1099\/vir.0.83507-0","article-title":"Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H","volume":"89","author":"K\u00f6ck","year":"2008","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2019.03.005_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10735-006-9059-0","article-title":"High expression of APOBEC3G in patients infected with hepatitis C virus","volume":"37","author":"Komohara","year":"2006","journal-title":"J. Histol."},{"key":"10.1016\/j.antiviral.2019.03.005_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.virol.2011.03.014","article-title":"Functional analysis of the two cytidine deaminase domains in APOBEC3G","volume":"414","author":"Li","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.03.005_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gky840","article-title":"Enterovirus 71 antagonizes the inhibition of the host intrinsic antiviral factor A3G","author":"Li","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2019.03.005_bib26","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1128\/JVI.02584-06","article-title":"Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation","volume":"81","author":"Luo","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.005_bib29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.virol.2005.01.011","article-title":"Complementary function of the two catalytic domains of APOBEC3G","volume":"333","author":"Navarro","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.03.005_bib30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cub.2004.12.068","article-title":"Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity","volume":"15","author":"Newman","year":"2005","journal-title":"Curr. Biol."},{"key":"10.1016\/j.antiviral.2019.03.005_bib31","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1128\/JVI.00465-08","article-title":"Reverse transcriptase- and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids","volume":"82","author":"Nguyen","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.005_bib32","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/hep.20580","article-title":"G to A hypermutation of hepatitis B virus","volume":"41","author":"Noguchi","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.03.005_bib33","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.3389\/fmicb.2016.02027","article-title":"APOBEC3G-Mediated G-to-A hypermutation of the HIV-1 genome: the missing link in antiviral molecular mechanisms","volume":"7","author":"Okada","year":"2016","journal-title":"Front. Microbiol."},{"issue":"17","key":"10.1016\/j.antiviral.2019.03.005_bib34","article-title":"APOBEC enzymes as targets for virus and cancer therapy","volume":"S2451\u20139456","author":"Olson","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.antiviral.2019.03.005_bib35","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/hep.24160","article-title":"Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus","volume":"53","author":"Peng","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.03.005_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1742-4690-2-32","article-title":"APOBEC3G targets human T-cell leukemia virus type 1","volume":"2","author":"Sasada","year":"2005","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2019.03.005_bib37","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature00939","article-title":"Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein","volume":"418","author":"Sheehy","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2019.03.005_bib38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.semcdb.2011.10.004","article-title":"Functions and regulation of the APOBEC family of proteins","volume":"23","author":"Smith","year":"2012","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.antiviral.2019.03.005_bib39","doi-asserted-by":"crossref","first-page":"8321","DOI":"10.1073\/pnas.0408223102","article-title":"Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo","volume":"102","author":"Suspene","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2019.03.005_bib40","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/10286020.2013.770737","article-title":"The antiviral effect of 7-hydroxyisoflavone against Enterovirus 71 in vitro","volume":"15","author":"Wang","year":"2013","journal-title":"J. Asian Nat. Prod. Res."},{"key":"10.1016\/j.antiviral.2019.03.005_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/s12985-016-0674-4","article-title":"Berberine inhibits enterovirus 71 replication by downregulating the MEK\/ERK signaling pathway and autophagy","volume":"14","author":"Wang","year":"2017","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2019.03.005_bib43","article-title":"Characterization of full-length enterovirus 71 strains from severe and mild disease patients in northeastern China","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.03.005_bib44","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1128\/JVI.06594-11","article-title":"The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication","volume":"86","author":"Wang","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.005_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083711","article-title":"Molecular epidemiology of enterovirus 71 infection in the central region of Taiwan from 2002 to 2012","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.03.005_bib48","article-title":"Host APOBEC3G protein inhibits HCV replication through direct binding at NS3","volume":"10","author":"Zhu","year":"2015","journal-title":"PLoS One"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219300269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219300269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T08:44:04Z","timestamp":1565167444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219300269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":41,"alternative-id":["S0166354219300269"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.03.005","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"APOBEC3G is a restriction factor of EV71 and mediator of IMB-Z antiviral activity","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}